Comparative Pharmacology
Head-to-head clinical analysis: HISTAFED versus TRINALIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HISTAFED versus TRINALIN.
HISTAFED vs TRINALIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HISTAFED is a combination of pseudoephedrine, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa causing vasoconstriction, and triprolidine, a first-generation antihistamine that competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, thereby preventing histamine-mediated effects.
TRINALIN is a combination of azatadine, a first-generation antihistamine that antagonizes histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that stimulates alpha-adrenergic receptors, causing vasoconstriction and reducing nasal congestion.
60 mg orally every 4 to 6 hours as needed; maximum 360 mg per day.
One tablet (azatadine 1 mg/pseudoephedrine 120 mg) orally every 12 hours. Not to exceed 2 tablets in 24 hours.
None Documented
None Documented
3-4 hours for pseudoephedrine component; shorter in children (2-3 h), prolonged in renal impairment
Terminal elimination half-life approximately 20-30 hours; clinical context: allows twice-daily dosing for sustained decongestant effect
Renal (approximately 65% as unchanged drug and metabolites), biliary/fecal (35%)
Renal: 70-80% as unchanged drug and metabolites; biliary/fecal: 20-30%
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine/Decongestant